Pulmonary Arterial Hypertension Market Size, Share, and Forecast by 2028
Pulmonary Arterial Hypertension Market: Strategic Insights
Pulmonary Arterial Hypertension Market
-
CAGR (2021 - 2028)5.8% -
Market Size 2021
US$ 7.37 Billion -
Market Size 2028
US$ 10.89 Billion
Market Dynamics
GROWTH DRIVERS
- Rising cases of pulmonary arterial hypertension (PAH)
- New targeted therapies for PAH treatment
FUTURE TRENDS
- Shift toward oral therapies for PAH management
- Development of new drug classes for PAH treatment
OPPORTUNITIES
- Growth of generics and biosimilars in PAH treatments
- Research into combination therapies and personalized medicine
Key Players
- Johnson Johnson
- Gilead Sciences Inc
- United Therapeutics Corp
- Bayer AG
- Aerami Therapeutics Holdings Inc
- Novartis AG
- GSK Plc
- Teva Pharmaceutical Industries Ltd
- Lupin Ltd
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Drugs - Endothelin Receptor Antagonists
- Prostacyclin and Prostacyclin Analogs
- sGC Stimulators
- pde-5 Dipsticks
Type - Branded and Generics
Route of Administration - Oral
- Intravenous/Subcutaneous
- Inhalational
Distribution Channel - Hospital Pharmacies and Clinics
- Online Pharmacies
- Retail Pharmacies
Get Free Sample For